Evidence map›Paper›PMID 38014348›Full record

ArticlebioRxiv : the preprint server for biology2024

An enterococcal phage protein broadly inhibits type IV restriction enzymes involved in antiphage defense.

Nathan P Bullen, Cydney N Johnson, Shelby E Andersen, Garima Arya, Sonia R Marotta, Yan-Jiun Lee, Peter R Weigele, John C Whitney, Breck A Duerkop

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Nathan P BullenDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada, L8S 4L8.
Cydney N JohnsonDepartment of Immunology and Microbiology, University of Colorado School - Anschutz Medical Campus, School of Medicine, Aurora, CO, USA, 80045.
Shelby E AndersenDepartment of Immunology and Microbiology, University of Colorado School - Anschutz Medical Campus, School of Medicine, Aurora, CO, USA, 80045.
Garima AryaDepartment of Immunology and Microbiology, University of Colorado School - Anschutz Medical Campus, School of Medicine, Aurora, CO, USA, 80045.
Sonia R MarottaDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada, L8S 4L8.
Yan-Jiun LeeResearch Department, New England Biolabs, Ipswich, MA, USA, 01938.
Peter R WeigeleResearch Department, New England Biolabs, Ipswich, MA, USA, 01938.ORCID 0000-0003-3696-4541
John C WhitneyDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada, L8S 4L8.ORCID 0000-0002-4517-8836
Breck A DuerkopDepartment of Immunology and Microbiology, University of Colorado School - Anschutz Medical Campus, School of Medicine, Aurora, CO, USA, 80045.ORCID 0000-0003-4030-9822
McMaster University · CAUniversity of Colorado Anschutz Medical Campus · USNew England Biolabs (United States) · USSt. Jude Children's Research Hospital · US

Funding

Mechanistic basis of bacteriophages for the decolonization of vancomycin resistant enterococci in the intestine.R01AI141479 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DUERKOP, BRECK A · 2018 to 2025
$4.4M
Molecular Pathogenesis of Infectious DiseasesT32AI052066 · NIAID · UNIVERSITY OF COLORADO DENVER · PI VAN DYK, LINDA F. · 2002 to 2022
$2.3M
Molecular mechanisms of lytic bacteriophage infection of enterococciF31AI157050 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JOHNSON, CYDNEY N · 2021 to 2022
$42k
NIAID NIH HHS F31 AI157050NIAID NIH HHS R01 AI141479NIAID NIH HHS T32 AI052066
6 · The paper itself

Abstract

The prevalence of multidrug resistant (MDR) bacterial infections continues to rise as the development of antibiotics needed to combat these infections remains stagnant. MDR enterococci are a major contributor to this crisis. A potential therapeutic approach for combating MDR enterococci is bacteriophage (phage) therapy, which uses lytic viruses to infect and kill pathogenic bacteria. While phages that lyse some strains of MDR enterococci have been identified, other strains display high levels of resistance and the mechanisms underlying this resistance are poorly defined. Here, we use a CRISPR interference (CRISPRi) screen to identify a genetic locus found on a mobilizable plasmid from

Indexed as

antiphageBacteriophagesEnterococcus faecalisplasmidtype IV restriction enzyme

Identifiers

PMID38014348
PMCPMC10680825
OpenAlexW4388773640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.